Abstract: Chemical syntheses of guide molecules are disclosed, along with compositions and methods relating thereto.

Abstract: The present disclosure relates to methods of assessing a sample of guide RNAs (gRNAs).

Abstract: The present disclosure relates to methods of assessing a sample of guide RNAs (gRNAs).

Abstract: The non-invasive methods described herein generally relates to methods of detecting bladder cancer or bladder cancer recurrence. The methods involve identifying a cutoff level for a protein biomarker parameter to provide a predetermined sensitivity for an assay, in which the measured biomarker parameter values below a defined cutoff level is indicative of the absence of cancer and measured biomarker parameter values above a defined cutoff level are indicative of the presence of cancer. The method can also involve establishing a cutoff level for two or more nucleic acid markers in which the nucleic acid markers increase the specificity of the assay without decreasing the sensitivity of the assay, and in which the cutoff level is indicative of the absence of cancer.

Abstract: Assays for detecting and grading disease by assessing amounts of GSTP1 nucleic acid and ADAM protein in a sample, and methods of using the assays. In some embodiments, the assays use single molecule sequencing to simultaneously assay both GSTP1 nucleic acid and ADAM protein. The methods are especially useful for detecting and grading cancers, for example, prostate cancer.

Abstract: The invention generally relates to methods for detecting mutations in a nucleic acid. In certain embodiments, the invention provides methods that involve forming a plurality of droplets, such that on average, each droplet includes a ratio of one nucleic acid template per bead, amplifying the template in the droplet to produce bead-bound amplicons, and sequencing at least one amplicon detect a mutation.

Abstract: The present invention generally relates to methods of screening for cancer. Methods of the invention involve identifying a threshold parameter of a protein and of two or more nucleic acids, where the threshold parameters are indicative of the absence of cancer, conducting an assay in a sample to determine a parameter of the two or more nucleic acids and a parameter of the protein, and identifying the sample as positive for cancer if the parameters of at least one of the nucleic acids and the protein present in the sample are greater than their respective threshold parameters. In certain aspects of the invention, the nucleic acids include FGFR3, TWIST1, and NID2. In certain aspects of the invention, the protein includes MMP2 or MMP9.

Abstract: The present invention generally relates to methods of screening for cancer recurrence. Methods of the invention involve identifying a threshold parameter of a protein and of two or more nucleic acids, where the threshold parameters are indicative of the absence of cancer, conducting an assay in a sample to determine a parameter of the two or more nucleic acids and a parameter of the protein, and identifying the sample as positive for cancer recurrence if the parameters of at least one of the nucleic acids and the protein present in the sample are greater than their respective threshold parameters. In certain aspects of the invention, the nucleic acids include FGFR3, Vimentin, and NID2. In certain aspects of the invention, the protein includes MMP2 or MMP9.

Abstract: The present invention generally relates to antibodies and use of these antibodies in diagnostic assays for various disease states, including cancer. In certain embodiments, the invention provides an isolated human or humanized antibody or functional fragment thereof including an antigen-binding region that is specific for an epitope on a protein, in which the epitope is specific to a tissue or body fluid and the epitope is indicative of a disease.

Abstract: The present invention provides a method for reducing angiogenesis using a phospholipase C.

Abstract: The present invention generally relates to serial analysis of biomarkers for disease diagnosis. In certain embodiments, the invention provides methods for diagnosing a disease including obtaining a sample from a subject, conducting a first assay to determine whether a first biomarker in the sample is positive or negative for a disease, and conducting a second assay to determine whether a second biomarker in the sample is positive or negative for the disease if the first assay produced a negative result.

Abstract: The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1, or a fragment thereof, which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the fragment has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 ?g/ml-20 ?g/ml, more preferably 75% inhibition, most preferably 95% inhibition.

Abstract: The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1, or a fragment thereof, which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the fragment has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 ?g/ml-20 ?g/ml, more preferably 75% inhibition, most preferably 95% inhibition.

Abstract: The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition.

Abstract: The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition.